Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RECOMBINANT HUMAN INTERLEUKIN-3 ENHANCES THE IN-VITRO SURVIVAL OF MONONUCLEAR PHAGOCYTES FROM THE PERIPHERAL-BLOOD OF VERY-LOW-BIRTH-WEIGHTPREMATURE-INFANTS AT BIRTH
Autore:
OMAR SA; FLEIT HB; KOBASIUK CD; LAGAMMA EF;
Indirizzi:
SUNY STONY BROOK,DEPT PEDIAT,HSC 11-060 STONY BROOK NY 11794 SUNY STONY BROOK,DEPT PEDIAT STONY BROOK NY 11794 SUNY STONY BROOK,DEPT PATHOL STONY BROOK NY 11794
Titolo Testata:
Biology of the neonate
fascicolo: 1, volume: 69, anno: 1996,
pagine: 1 - 11
SICI:
0006-3126(1996)69:1<1:RHIETI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; HUMAN CORD BLOOD; MATURE MARROW NEUTROPHILS; TUMOR NECROSIS FACTOR; GRANULOCYTE-MACROPHAGE; INTERFERON-GAMMA; GENE-EXPRESSION; T-CELLS; NEUTROPENIA; MONOCYTES;
Keywords:
INTERLEUKIN; MONONUCLEAR PHAGOCYTES; NEONATAL BLOOD; PROGENITOR CELLS; CD34;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
44
Recensione:
Indirizzi per estratti:
Citazione:
S.A. Omar et al., "RECOMBINANT HUMAN INTERLEUKIN-3 ENHANCES THE IN-VITRO SURVIVAL OF MONONUCLEAR PHAGOCYTES FROM THE PERIPHERAL-BLOOD OF VERY-LOW-BIRTH-WEIGHTPREMATURE-INFANTS AT BIRTH", Biology of the neonate, 69(1), 1996, pp. 1-11

Abstract

We examined the effects of recombinant human IL-3 (rhIL-3) on peripheral blood mononuclear cells (MNC) isolated from 18 premature human Interleukin 3 (IL-3) is a pluripotent hematopoietic growth factor that stimulates proliferation, differentiation, and function of multiple celllineages. newborns with birth weights between 600 and 1,500 g at birth and at 2 and 4 weeks of age, from 7 full-term neonates, and from 26 normal adult volunteers. After 2 weeks in liquid culture, rhIL-3 treatment was associated with a six- to nine-fold increase in the survival of MNC from very low birth weight (VLBW) neonates. In the absence of rhIL-3, VLBW neonatal MNC exhibited a low survival rate. MNC from 6 of 7 full-term neonates responded similarly to rhIL-3 with an eight-fold increase in survival. In contrast, rhIL-3 showed only a 20-30% increase in the survival of adult MNC (p = NS). When analyzed by immunofluorescent microscopy using monoclonal antibodies to phenotypic markers characteristic of individual MNC lineages, 70-80% of the surviving VLBW neonatal MNC were mononuclear phagocytes, while 70-80% of the survivingadult MNC were T cells. Full-term MNC cultures displayed a populationof cells with an intermediate phenotype. Following rhIL-3 treatment, surviving MNC from term neonates displayed 35% T cells and 53% mononuclear phagocytes which was not significantly different from untreated MNC. rhIL-3 treatment was associated with a seven- to twelve-fold increase in the number of progenitor cells (CD34+) from VLBW neonatal bloodand a three- to five-fold increase in the number of adult progenitor cells. Full-term neonates had a lower percentage of CD34+ cells than VLBW neonates, and this was not significantly altered by the rhIL-3 treatment. We conclude that rhIL-3 increases the number of mononuclear phagocytes that survive in culture following isolation from the peripheral blood of VLBW neonates. These in vitro studies may have a predictive value for in vivo studies utilizing combinations of hematopoietic growth factors to enhance neonatal host defense.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 09:57:10